XML 28 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net income (loss) $ 267,303 $ 334,757 $ 516,424
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Depreciation and amortization of real estate, in-place lease, and other intangibles 1,057,205 749,901 710,569
Stock-based compensation amortization expense 15,543 14,480 26,456
Merger-related post-combination stock compensation expense 16,223 0 0
Amortization of deferred financing costs and debt discounts (premiums) 28,974 11,916 10,881
Straight-line rents (41,276) (14,387) (49,183)
Amortization of non-refundable entrance fees and above (below) market lease intangibles (119,750) (108,988) (102,747)
Equity loss (income) from unconsolidated joint ventures 1,515 (10,204) (2,049)
Distributions of earnings from unconsolidated joint ventures 12,000 910 943
Loss (gain) on sale of real estate under direct financing leases 0 0 (22,693)
Deferred income tax expense (benefit) (1,693) (14,605) (6,001)
Impairments and loan loss reserves (recoveries), net 22,978 (5,601) 7,004
Loss (gain) on sales of real estate, net (178,695) (86,463) (10,422)
Loss (gain) upon change of control, net (77,548) (234) (311,438)
Casualty-related loss (recoveries), net 29,076 (3,085) 7,168
Other non-cash items (6,133) 4,900 6,489
Changes in:      
Decrease (increase) in accounts receivable and other assets, net (40,860) (21,566) (17,433)
Increase (decrease) in accounts payable, accrued liabilities, and deferred revenue 85,635 104,511 136,293
Net cash provided by (used in) operating activities 1,070,497 956,242 900,261
Cash flows from investing activities:      
Acquisitions of real estate (6,787) (15,847) (178,133)
Development, redevelopment, and other major improvements of real estate (597,494) (731,206) (861,636)
Leasing costs, tenant improvements, and recurring capital expenditures (115,784) (113,596) (108,510)
Proceeds from sales of real estate, net 648,548 141,651 47,885
Proceeds from the South San Francisco JVs transaction, net 0 0 125,985
Proceeds from the Callan Ridge JV transaction, net 125,662 0 0
Investments in unconsolidated joint ventures (61,602) (88,391) (21,143)
Distributions in excess of earnings from unconsolidated joint ventures 22,906 20,640 12,518
Proceeds from insurance recovery 8,711 24,980 1,450
Proceeds from sales/principal repayments on loans receivable and marketable debt securities 93,445 204,865 115,988
Investments in loans receivable and other (52,189) (19,850) (10,747)
Cash paid in connection with the Merger, net (179,215) 0 0
Net cash provided by (used in) investing activities (113,799) (576,754) (876,343)
Cash flows from financing activities:      
Borrowings under bank line of credit and commercial paper 3,741,250 10,344,705 15,882,153
Repayments under bank line of credit and commercial paper (4,311,250) (10,620,311) (16,052,522)
Issuances and borrowings of term loans, senior unsecured notes, and mortgage debt 750,000 743,778 500,000
Repayments and repurchases of term loans, senior unsecured notes, and mortgage debt (26,780) (90,089) (5,048)
Payments for deferred financing costs (19,784) (7,322) (4,171)
Issuance of common stock and exercise of options, net of offering costs 317 278 308,100
Repurchase of common stock (190,690) (6,524) (67,838)
Dividends paid on common stock (794,783) (657,021) (648,047)
Distributions to and purchase of noncontrolling interests (89,708) (45,282) (30,549)
Contributions from and issuance of noncontrolling interests 12 489 1,390
Net cash provided by (used in) financing activities (941,416) (337,299) (116,532)
Net increase (decrease) in cash, cash equivalents, and restricted cash 15,282 42,189 (92,614)
Cash, cash equivalents, and restricted cash, beginning of year 169,023 126,834 219,448
Cash, cash equivalents, and restricted cash, end of year $ 184,305 $ 169,023 $ 126,834